Genistein (GEN) has been previously reported to enhance the radiosensitivity of cancer cells; however, the detailed mechanisms remain unclear. Here, we report that GEN treatment inhibits the cytoplasmic distribution of Bcl-xL and increases nuclear Bcl-xL in non-small cell lung cancer (NSCLC). Interestingly, our in vitro data show that ionizing radiation IR treatment significantly increases IR-induced DNA damage and apoptosis in a low cytoplasmic Bcl-xL NSCLC cell line compared to that of high cytoplasmic Bcl-xL cell lines. In addition, clinical data also show that the level of cytoplasmic Bcl-xL was negatively associated with radiosensitivity in NSCLC. Furthermore, we demonstrated that GEN treatment enhanced the radiosensitivity of NSCLC cells partially due to increases in Beclin-1-mediated autophagy by promoting the dissociation of Bcl-xL and Beclin-1. Taken together, these findings suggest that GEN can significantly enhance radiosensitivity by increasing apoptosis and autophagy due to inhibition of cytoplasmic Bcl-xL distribution and the interaction of Bcl-xL and Beclin-1 in NSCLC cells, respectively.
, and it attenuates inflammatory injuries in normal tissue caused by ionizing radiation (IR) 4 . These anti-tumor effects of GEN were identified in both in vitro and in clinical cases of a wide variety of cancer types, including prostate cancer, breast cancer, colon cancer, gastric cancer, lung cancer, pancreatic cancer, and lymphoma [5] [6] [7] [8] . Studies show that GEN improves the effectiveness of either radio-or chemotherapy in cancer cells by enhancing apoptosis and autophagy 9, 10 . However, the detailed mechanism by which GEN enhances the apoptosis and autophagy induced by oncotherapy in cancer remains unclear.
Autophagy is the lysosomal degradation pathway 11 , and it exerts opposing functions in response to IR-induced stress in tumor cells. One such function is cytoprotective; inhibition of this activity can sensitize cancer cells to treatment modalities. However, excessive autophagy promotes the death of tumor cells 12, 13 . In lung cancer, studies show that increased autophagy dramatically abrogates radioresistance 14, 15 . Apoptosis is also a desired effect of anti-tumor therapy, and the relationship between autophagy and apoptosis may depend on the biological context in which these events occur 16, 17 . The dysregulation of apoptosis is a common phenomenon in cancer cells and is one mechanism by which cancer cells can resist oncotherapy. Bcl-xL is an anti-apoptotic protein, and increased expression of Bcl-xL was closely associated with radio-and chemotherapy resistance 18 . Studies show that a combination treatment of IR and a Bcl-xL inhibitor exerts a synergistic effect by activating the Bak-apoptosis pathway in cancer cells that are resistant to oncotherapy 19, 20 . Bcl-xL also regulates cellular autophagy by interacting with Beclin-1 to inhibit the initiation of Beclin-1-mediated autophagy 21, 22 . Studies show downregulation of Bcl-xL expression with specific siRNAs can activate autophagy and promote cancer cell death 23, 24 , suggesting that Bcl-xL plays an key role in the crosstalk between autophagy and apoptosis.
Our study shows that GEN treatment inhibits cytoplasmic translocation of Bcl-xL in NSCLC cells, and the level of cytoplasmic Bcl-xL was negatively correlated with radiosensitivity in NSCLC. In addition, our data show that GEN treatment can enhance IR-induced cell death in NSCLC cells by simultaneously activating apoptosis and autophagy. Furthermore, we identified that increased autophagy by GEN is due to the promotion of Bcl-xL dissociation from Beclin-1, thereby activating Beclin-1 induced autophagy.
Results
GEN reduced cytoplasmic of Bcl-xL levels in NSCLC cells. Bcl-xL is an important anti-apoptotic protein. Our in vitro experiment shows that GEN treatment significantly reduces the levels of cytoplasmic Bcl-xL while simultaneously increasing the nuclear Bcl-xL levels in a time-and dose-dependent manner in A549 cells (Fig. 1a,b) . However, GEN does not affect the total expression of Bcl-xL in A549 cells (Fig. 1a,b) . These results, we confirmed in another NSCLC cell line, Calu-1. As shown in Fig. 1c , similar with A549 cells, GEN treatment significantly reduced cytoplasmic levels of Bcl-xL as well as increased nuclear Bcl-xL levels in Calu-1 cells, however, does not affect the total expression of Bcl-xL in Calu-1 cells. Finally, we used immunofluorescence analysis to confirm the effect of GEN on Bcl-xL subcellular distribution. As shown in Fig. 1d , GEN treatment significantly inhibited cytoplasm distribution of Bcl-xL while increasing nuclear Bcl-xL levels in A549 cells in a dose-dependent manner. Taken together, these results suggest that GEN affects the subcellular distribution of Bcl-xL in NSCLC cells.
Cytoplasmic Bcl-xL levels are negatively associated with radiosensitivity in NSCLC. Next, we investigated the correlation between the levels of cytoplasmic Bcl-xL and radiosensitivity in NSCLC cell lines. First, we measured the expression level of cytoplasmic Bcl-xL in different NSCLC cell lines. As shown in Fig. 2a , H460 cells have lower cytoplasmic Bcl-xL levels and higher nuclear Bcl-xL levels compared to other NSCLC cells, including H1975, Calu-1 and A549 cells. Interestingly, the CCK-8 assay shows that H460 cells are more sensitive to IR treatment compared to the NSCLC cell lines that have higher basal cytoplasmic Bcl-xL levels (Fig. 2b) . Consistent with this result, treatment with IR significantly induced more expression of the pro-apoptotic protein cleaved PARP, cleaved caspase-3 ( Fig. 2c ) and DNA damage (Fig. 2d-f ) in H460 cells compared to the other NSCLC cell lines. Furthermore, we investigated the impact of cytoplasmic Bcl-xL levels on the objective response rate (ORR) of radiotherapy in NSCLC patents. The expression of Bcl-xL was analyzed in tumor samples from 29 NSCLC patients using immunohistochemistry and categorized into two groups based the immunostaining score (Fig. 3a) . As shown in Fig. 3b, 22 and 7 cases of the 29 tested NSCLC samples showed low and high expression of cytoplasmic Bcl-xL, respectively. Interestingly, in the cytoplasmic Bcl-xL high expression group, only 28.57% of NSCLC patients responded to radiotherapy, whereas the remaining 75.9% of patients experienced either recurrence or new metastasis (Fig. 3b) . In contrast, 90.9% of NSCLC patients in the cytoplasmic Bcl-xL low expression group responded to radiotherapy, whereas the remaining 9.1% patients did not respond (Fig. 3b ). These findings suggest that level of cytoplasmic Bcl-xL was negatively associated with radiosensitivity in NSCLC.
GEN enhances the radiosensitivity of NSCLC cells by enhancing IR-induced DNA damage and apoptosis. We next investigated whether the combination of IR and GEN could exert a synergistic effect on inhibition of NSCLC cell viability. As shown in Fig. 4a and b, the combination of GEN and IR treatment significantly inhibited more cell growth and induced more apoptosis compared to either GEN or IR treatment alone in A549 cells. Consistent with these results, the combination treatment of GEN and IR significantly increased the expression of the DNA damage marker protein γ-H2AX, the pro-apoptotic protein Bax, cleaved-PARP and -caspase-3 in A549 cells compared to cells receiving solo treatments of either GEN or IR ( Fig. 4c and d) . Additionally, we detected significantly reduced levels of cytoplasmic Bcl-xL in the GEN and IR combination treatment group (Fig. 4d) . Furthermore, we confirmed that synergistic inhibition effect of combination of IR and GEN treatment on NSCLC growth using A549 xenograft model. Consistent with in vitro cell viability assay, the combination treatment of GEN and IR significantly inhibited tumor growth in xenogaft model (Fig. 4e) . Taken together, these findings suggest that GEN can enhance the radiosensitivity of NSCLC cells through reducing plasmic Bcl-xL levels and promoting IR-induced DNA damage and apoptosis.
GEN enhances the radiosensitivity of NSCLC cells through promote autophagy. Finally, we investigated whether GEN affects IR-induced autophagy in NSCLC cells because previous studies have shown that GEN can affect chemotherapy-induced autophagy 10 . As shown Fig. 5a , the combined treatment of GEN and IR significantly increased the level of autophagy maker protein LC3II while decreasing p62 compared to either control cells or cells receiving a single treatment. Consistent with this Western blot data, IF staining show that LC3 expression was significantly increased in GEN and IR combined treatment group compare to either control or single treatment (Fig. 5b) , suggesting that the combination of GEN and IR treatment exerts synergistic effects on autophagy. This phenomenon was further confirmed by flow cytometry (Fig. 5c) . Because the AKT/mTOR pathway is involved in Beclin-1 induced autophagy, we investigated the effects of GEN and IR combination on the AKT/mTOR/Beclin-1 axis in NSCLC cells. Our results show that only Beclin-1 expression was significantly increased after treatment with the GEN and IR combination compared to the control and single treatment groups (Fig. 5d) . Next, we investigated the effects of GEN and IR combination on Bcl-xL/Beclin-1 binding because studies show that Bcl-xL inhibits Beclin-1-mediated autophagy by binding to Beclin-1 to inhibit autophagosome formation 21, 25 . As shown in Fig. 5e , the combination of GEN and IR significantly promotes the dissociation of Bcl-xL/Beclin-1 in A549 cells. Together, these data suggest that GEN can enhance IR-induced autophagy by promoting the dissociation of Bcl-xL and Beclin-1.
Then, we investigated whether autophagy plays a critical role on the cell death induced by the combination of IR and GEN. Here, we used hydroxychloroquine (CQ) as an autophagy inhibitor (Fig. 6a) . Our data show that inhibition of autophagy by CQ abolished IR and GEN combination treatment induced high expression of cleaved PARP and cleaved caspase-3 in A549 cells (Fig. 6b) . In addition, the flow cytometry results show that the inhibition of autophagy dramatically reduced apoptosis induced by the GEN and IR combination treatment ( Fig. 6c  and d) . Those data indicate that the combined GEN and IR treatment-induced apoptosis is partially due to the stimulation of autophagy in NSCLC cells.
Discussion
Radiotherapy remains one of the prime treatment modalities for many cancers. However, the clinical concern is the subset of cancer patients who show resistance to radiotherapy. GEN is an isoflavone isolated from soy, and previous reports have highlighted that GEN can enhance the efficacy of radiotherapy in numerous tumor types. Consistent with previous reports, we also demonstrated the significantly enhanced efficacy of radiotherapy when combined with GEN in NSCLC cells. More importantly, for the first time, we demonstrated that GEN enhanced the radiosensitivity of NSCLC cells by simultaneously stimulating apoptosis and autophagy. Interestingly, studies show that GEN not only promotes the therapeutic efficacy of radiation in lung cancer but also protects normal lung tissues from radiation 26 . Together, these findings suggest that GEN treatment may be a useful strategy to enhance radiotherapy efficacy and protect normal tissues from IR in NSCLC patients. In the current study, we also clarified the radiosensitivity regulatory mechanism of GEN in NSCLC cells. Bcl-xL is a major anti-apoptotic protein. Studies show that IR treatment induces Bcl-xL expression, thereby causing radioresistance of NSCLC cells 27 . In addition, inhibiting the Bcl-xL pathway could improve resistance to radiotherapy in lung cancer patients 27 , suggesting that Bcl-xL plays an important role in the development of radioresistance. Previous results show that GEN treatment suppresses Bcl-xL expression to induce apoptosis in hepatoma cells 28 . Contrary to previous reports, we did not observe changes in the total expression of Bcl-xL after GEN treatment in NSCLC cells. However, our Western blot and IF analyses clearly show that GEN treatment reduces cytoplasmic levels Bcl-xL as well as increases nuclear Bcl-xL levels in NSCLC cells. In addition, our in vitro data show that the level of cytoplasmic Bcl-xL was negatively associated with IR-induced DNA damage and apoptosis. Consistent with the in vitro experiments, our clinical data revealed a significant correlation between the low cytoplasmic Bcl-xL levels and the ORR to radiotherapy. According to Subramanian et al., Bcl-xL interacts with pro-apoptotic proteins, including Bim and Bid, in the cytoplasm 29 , suggesting that cytoplasmic Bcl-xL plays a crucial role in apoptosis. Nuclear Bcl-xL also plays an important role in DNA damage. Nuclear Bcl-xL can inhibit the DNA damage repair gene APE1 by interacting with APE1, thus enhancing oncotherapy-induced DNA damage and apoptosis 30 . This suggests that not only total Bcl-xL levels but the distribution of Bcl-xL are also an important factor in oncotherapy-induced apoptosis. Together, these findings suggest that GEN enhances the radiosensitivity of NSCLC cells through stimulating apoptosis due to the subcellular distribution of Bcl-xL. However, the mechanism of how GEN regulates the cellular distribution of Bcl-xL is unclear and requires further research.
Autophagy is the process of self-digestion as it relates to both cell survival and cell death and plays an important role in the regulation of cell radiosensitivity. Our results show that GEN treatment promotes both autophagy and apoptosis in NSCLC cells and that the autophagy stimulates apoptosis. Cytoplasmic Bcl-xL plays a crucial role in maintaining homeostasis of apoptosis and autophagy during stress 21 . Studies show that Bcl-xL can binding to Beclin-1 and inhibit Beclin-1 mediated autophagy 21, 31 . Interestingly, studies show that increased autophagy by overexpression of Beclin-1 can significantly abrogate the radioresistance of lung cancer cells 14 , suggesting that Beclin-1-mediated autophagy plays an important role in the radioresistance of lung cancer cells. Here, our data clearly show that GEN treatment can increase autophagy, and inhibiting autophagy can partially abrogate the cell death induced by the combined IR and GEN treatment in NSCLC cells. In addition, our data show that GEN 
in NSCLC cells. However, the mechanism of how GEN affect the interaction of Bcl-xL and Beclin-1 is still unclear.
In conclusion, GEN inhibits the cytoplasmic distribution of Bcl-xL, and the reduced levels of cytoplasmic Bcl-xL are closely associated with the radiosensitivity of NSCLC cells. GEN treatment also enhanced radiosensitivity by increasing DNA damage induced apoptosis and Beclin-1-mediated autophagy due to the promoted dissociation of Bcl-xL and Beclin-1. Our findings suggesting that GEN could be a potent therapeutic agent to enhance the sensitivity of radiotherapy in resistant NSCLC.
Materials and Methods
Materials. Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Invitrogen (Grand Island, NY, USA). Genistein (GEN), hydroxychloroquine, penicillin, streptomycin and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Immunoprecipitation (IP) lysis buffer, Dynabeads ® Protein G, fluorescence isothiocyanate (FITC)-Annexin V and PI were purchased from Life Technologies Corporation (Carlsbad, CA, USA). Antibody against Bcl-xL was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against mTOR, p-mTOR, p62, Bax, β-tubulin, p-Akt, Akt, PARP, horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit IgG antibodies were from Abcam (Cambridge, MA, USA). Beclin1, LC3, γ-H2AX, and caspase-3 were purchased from Cell Signaling Technology (Danvers, MA, USA). Cyto-ID Autophagy Detection Kits were purchased from Enzo Life Sciences (Farmingdale, NY, USA), and NE-PER(R) Nuclear and Cytoplasmic Extraction Kits were from Thermo Scientific Pierce (Rockford, IL, USA).
Cell culture. Human NSCLC cell line A549, Calu-1, H1975 and H460 were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). All cells were cultured in MEM medium containing 10% FBS and 50 mg/mL penicillin/streptomycin, in a 5% CO2, 37 °C humidified incubator.
Western blot analysis. Equal amounts of proteins were separated on SDS-polyacrylamide gels, and transferred to PVDF membranes, then blocked with 5% nonfat dry milk in TBST for 1 h at room temperature. Next, membranes were incubated with primary antibody for overnight at 4 °C, followed by 1 h incubation at room temperature with horseradish peroxidase-conjugated secondary antibodies. Finally reacted with chemiluminescent staining reagents. The stained protein bands were visualized with BioMax-Light film (Eastman Kodak Co., Rochester, NY, USA), and the staining intensities of the various protein bands were obtained using Gel Doc 2000 apparatus and software (Quantity One, Bio-Rad; Hercules, CA, USA).
Co-immunoprecipitation (Co-IP) assay. Cells were harvested by scraping, and washed once with ice-cold phosphate-buffered saline (PBS) solution; after which, cells were incubated in IP lysis buffer (Life Technologies) supplemented with a protease inhibitor cocktail (Pierce). Protein concentrations were determined using the Bradford assay (Bio-Rad, Hercules, CA, USA). A 50 μL (1.5 mg) aliquot of Dynabeads ® was transferred to a tube, which was then placed on a magnet to separate the beads from the solution, and the supernatant was removed. Next, Bcl-xl or Beclin-1 antibody in 200 μL of PBS containing Tween ® -20 was added to the tube, which was then incubated with rotation for 2 h at 4 °C. After removing the supernatant, an equal volume of protein extract was added to the tube, which was then incubated with rotation overnight at 4 °C. Next, the Dynabeads ® -Bcl-xL-protein or Dynabeads ® -Belin1-protein complex was washed 3 times with 200 μL of washing buffer, the supernatant was removed, and 20 μL of elution buffer, 10 μL of premixed NuPAGE ® LDS sample buffer, and NuPAGE ® sample reducing agent were added to the tube, which was then heated at 70 °C for 10 min. Finally, the tube was placed on a magnet and the sample was loaded onto a gel.
CCK-8 assay. Cells were seeded in 96-well plates at density 2 × 10 3 /well. After 12 hrs of transfection, cells were treated as indicated. Cell viability was detected using CCK-8 kit according to manufacture's intruction. The absorbance of each well was determined at 450 nm using a Microplate Reader 550 (Bio-Rad Laboratories).
Comet assay. A549 cells, H1975 cells, Calu-1 and H460 cells were rinsed twice with ice-cold PBS and harvested. The cells were then re-suspended, and each suspension was exposed to IR (2 GY). Either immediately after treatment or after 2-hour post-treatment recovery incubation at 37 °C, each cell suspension was placed on ice, or an alkaline comet assay was performed using a Comet assay kit (Trevigen; Gaithersburg, MD, USA) according to the manufacturer's instructions with modifications.
Flow cytometry analysis. A549 cells were cultured in six-well plates and treated as indicated. Then, cells were harvested and resuspended in PBS, stained using an annexin V/propidium iodide (PI) kit (Life Technologies) following the manufacturer's instructions, and analyzed by flow cytometry.
Immunofluorescence (IF) and Immunohistochemistry (IHC) analysis. For IF analysis, A549
cells were treated with indicated concentrations of GEN. After 6 h of GEN treatment, cells were fixed with 3.7% paraformaldehyde in PBS for 30 min, permeabilized with 0.2% Triton X-100 in PBS for 10 min, blocked with 5% BSA in PBS for 30 min, and incubated with anti-Bcl-xl antibody overnight at 4 °C. After incubation, the cells were flooded with Texas-Red-labeled secondary antibody for 60 min, then stained with DAPI4 (6-diamidino-2-phenyl-indole dihydrochloride). Fluorescent images were observed using a laser-scanning confocal microscope (Olympus FV500, Chongqing, China) equipped with appropriate filters. The expression of cytoplasmic Bcl-xl in human specimens were measured by IHC. After deparaffinization and blocking, slides were incubated Bcl-xl monoclonal antibody (1:200 dilution)for overnight at 4 °C; incubated with 1:50 dilution of goat anti-mouse secondary antibody for 1 h at room temperature. Finally, slides were incubated with 3,30-diaminobenzidine (DAB) substrate. Scoring for cytoplasmic Bcl-xl staining was performed as described previously by three professional pathologist Animal experiments. For the subcutaneous tumor growth assay, 2 × 10 6 A549 cells in 0.1 mL of phosphate-buffered saline (PBS) were subcutaneously injected into 6-weeks old female nude mice (5 mice per group). When tumors reached a size of approximately 100 mm 3 , mice were randomized into the following four treatment groups and started to genisetin treatment: (a) control; (b) genestein only; (c) radiation only; (d) combination of genestin and IR. Genistein was injected to mice every day by I.P. injection (100 mg/Kg body weight) 4 , until the end of animal experiment. After 3 days of genistein treatment, tumors were irradiated with 6 Gy radiation. After 20 dyas of genistein treatment, mice were sacrificed. The tumor size were measured using caliper every 4 days. Animal studies were conducted according to humane animal care standards and were approved by the Ethics of Committee of Third Military Medical University, China.
Statistical analysis.
Results are represented by mean ± S.D. Statistical significance was tested by one-way ANOVA, with p-value of less than 0.05 considered statistically significant.
